Table 2.
Investigator assessed best overall response
| DLBCL | FL | Other iNHL | MCL | Total | |
|---|---|---|---|---|---|
| N = 35 | N = 34 | N = 11 | N = 12 | N = 92 | |
| Best overall response | |||||
| Complete response | 2 (6) | 3 (9) | 2 (18) | 0 | 7 (8) |
| Partial response | 7 (20) | 7 (21) | 1 (9) | 0 | 15 (16) |
| Stable disease | 5 (14) | 16 (47) | 4 (36) | 6 (50) | 31 (34) |
| Progressive disease | 11 (31) | 4 (12) | 3 (27) | 5 (42) | 23 (25) |
| Not evaluablea | 10 (29) | 4 (12) | 1(9) | 1 (8) | 16 (17) |
| ORR (all patients) | 9 (26) | 10 (29) | 3 (27) | 0 | 22 (24) |
| ORR (assessable patients onlyb) | 9 (36) | 10 (33) | 3 (30) | 0 | 22 (29) |
| DCR (all patients) | 14 (40) | 26 (76) | 7 (64) | 6 (50) | 53 (58) |
Data are number of patients (%).
a
Radiological post-baseline response assessment not performed/data unavailable.
b
Post hoc sensitivity analysis excluding patients without post-baseline radiological tumor assessment.
DLBCL, diffuse large B-cell lymphoma; DCR, disease control rate (complete + partial responses + stable disease); FL, follicular lymphoma; iNHL, indolent non-Hodgkin’s lymphoma; MCL, mantle cell lymphoma; ORR, objective response rate (complete + partial responses).